Global Blood Therapeutics, Inc. (GBT), is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. More »

Featured News

Recent News

02/07/18GBT Announces Participation at the Leerink Partners 7th Annual Global Healthcare Conference
01/09/18GBT Receives FDA Breakthrough Therapy Designation for Voxelotor for Treatment of Sickle Cell Disease (SCD)
01/03/18GBT to Present at the 36th Annual J.P. Morgan Healthcare Conference
12/22/17GBT Appoints Wendy L. Yarno to Board of Directors

More »

Media Resources

Stay Informed

Sign up to receive email updates about ongoing sickle cell disease clinical studies, awareness and educational information and GBT news at:

Media Contact

Julie Normart